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The Event Free Survival (PFS) at 5 years of children treated for Acute Lymphoblastic 
Leukaemia (ALL) in High Income Countries (HIC) is > 80% (1, 2), and increasingly refined risk 
stratification has ensured that the intensity of treatment given maximises cure rates and 
minimises toxicity. Supportive care and health infrastructure are a vital part of this 
advancement in care, but in Low Income Countries (LIC) such as Malawi, a similar range of 
chemotherapeutic agents and supportive care is not available. In addition, the lack of timely 
laboratory diagnostic testing, the inability of families to access basic care, the long course of 
treatment and the existence of co-morbidities in many of the children has meant that 
treatment of acute lymphoblastic leukaemia is extremely challenging (3).  
 
In 2010, the first treatment protocol for ALL in Malawi was introduced at the Queen Elizabeth 
Central Hospital (QECH) in Blantyre (4). This first protocol to treat ALL in Malawi was mindful 
of the prevailing infrastructure and set realistic goals of inducing remission in 50% of children 
and to assess toxicity. Based on outcomes for ALL protocol 1, incremental refinements to this 
first protocol were introduced in subsequent protocols, numbered 2 and 3, with the aim to 
improve both overall and EFS  (Details of treatment are shown in Supplementary Figure 1). 
This letter reports the results of ALL treatment over the past 9 years at the QECH, as well as 
describing the difficulties in establishing and maintaining a treatment programme for 
children with haematological malignancies in a low-income setting. The QECH is a large, 
public, government referral hospital in Blantyre, Malawi. The paediatric oncology unit is a 
23-bedded unit housed within the paediatric department which receives about 320 new 
patients a year. All children < 16 years of age with a suspected cancer diagnosis are 
admitted to the oncology ward; all children with a confirmed diagnosis of ALL were included 
in this study. The entire cost of treatment and hospital stay is free of charge to the families 
and is approximately £1000 (without travel costs) per patient, paid by a combination of 
governmental health budget money and charities.  Despite some travel refunds and food 
provided in hospital, there are considerable out of pocket costs including food en route or 
any accommodation that may be necessary. Informed consent was obtained from the 
patients/guardians prior to commencement of treatment and all three ALL treatment 
protocols were approved by the local ethics committee.   
Initial investigations and details of the treatment protocols as well as details of the statistical 
analyses can be found in the supplementary material.  
Forty-two children (December 2009 – December 2012) were treated on the ALL 1 protocol 
(all based on intention to treat), 10 (January – July 2013) on ALL 2 and 145 on ALL 3 (August 
2013 - October 2019). Since ALL 1 has been previously reported (4) and ALL 2 was an interim 
protocol with only 10 patients enrolled, we confined further analysis to ALL 3 patients. The 
clinical characteristics of the cohort and outcomes can be seen in Table 1. Of the 101 patients 
completing 4 weeks of treatment, 97 appeared to be in remission on morphological 
examination of their bone marrow at week 5. Eleven patients (8%) died before treatment 
could be started, 37 (26%) died in induction, 13 (9%) died immediately post intensification 
prior to count recovery and 74 (38%) at other time points. Of the patients dying during 
induction, 14 (38%) were NCI low-risk (age< 10 years and WBC < 50 x 109/L) and 23 (62 %) 
high-risk, which is the same proportion as the overall cohort.  It was difficult to ascertain the 
cause of death during induction, although in 10 (27%) of the children, sepsis was the major 
cause and 2 (5%) disease the major cause; the remainder were likely to be due to a 
combination of these factors. In the absence of routine electrolytes, the incidence of tumour 
lysis was not known. Of the 87 children dying after count recovery following week 5 of 
treatment, 61 (70%) were presumed to have died due to disease recurrence and 26 (30%) of 
presumed infection, some of whom had community-acquired infections. Seventy-two 
children (48%) completed intensification (Supplementary Figure 2). Sixteen patients (11%) 
failed to complete treatment for non-medical reasons. Contributing reasons were financial 
issues, the stress of being away from home responsibilities and the lack of easy access to 
return journeys. Of the 129 remaining patients, 26 (18%) were still alive when last seen, with 
FU times ranging from 29 to 1492 days (median 622 days). Nineteen patients are known to 
have relapsed (83-1349 days after treatment began, median 490 days), 5 of whom were alive 
when last seen.  For the total cohort of 145 patients treated with ALL protocol 3, event free 
survival (EFS) at 24 months was 27 %, (95% CI 19-39), demonstrating a significant 
improvement in EFS compared to protocols 1 (n=42; EFS 10%, 95%CI 3-29) and 2 (n=11; EFS 
10%, 95%CI 2-66, overall p=0.03).  
Retrospective genetic analysis of a portion of the cohort is described in the supplementary 
material.  
Setting up an ALL treatment programme in a LIC is a challenging endeavour, during which 
many factors have to be considered. In contrast to HIC, patients typically present late and 
with significant co-morbidities in LIC treatment centres. This was clearly demonstrated in our 
study, with the initial very high death rate during induction therapy (Protocol 1, 14/42 (33%)) 
which, although now reduced due to improved supportive care (Protocol 3, 38/145 (26%)), is 
still unacceptably high.  
  
The diagnosis of ALL is challenging in LIC. We developed a remote pathology service which 
provided some level of diagnostics in which blood and bone marrow films are examined 
within 24-48 hours, as described in the supplementary material (5). Treatment was often 
commenced with the prednisolone pre-phase on the basis of clinical suspicion, whilst waiting 
for the blood films to be reported in Newcastle. Flow cytometry and genetic analysis are not 
available routinely in Malawi, and so meaningful stratification remains challenging. However, 
a full blood analyser was been installed in the paediatric department in 2018, which allows 
more timely blood counts to be performed.   
 
Supportive care is vital in treating children with ALL. Antibiotics should be given promptly, 
hydration used with close monitoring and allopurinol given to help prevent the nephrotoxic 
effects of tumour lysis. Granulocyte colony stimulating factor is not routinely available and 
was used when available in a small number of carefully selected children post 
intensification.  The nurse to patient ratio is much reduced in LIC (6) so close attention to 
each individual child is not easily possible. The recommendation is 1 nurse to 5 patients in 
LIC (6) although in the Blantyre unit this is usually 1:10, with a lower staffing ratio at night 
and the weekends. The number of medical staff is also reduced, there is one consultant 
(GC), one registrar (on 6 months rotation), one intern (for a 1-month rotation and 
often ‘post take’ or off) as well as 1 clinical officer (EC). These are areas which also need to 
be addressed to improve the service. 
 
There is a relatively high incidence of pre-treatment deaths (N=11; 8%). Also, the provision of 
maintenance treatment was compromised by the inability to acquire a rapid blood count to 
adjust doses of 6-mercaptopurine and methotrexate.  Parents and family members often 
have very few resources for travel to and from the hospital for prolonged treatment (the 
children travel up to 300 miles, often by infrequent and relatively expensive public transport 
or minibus), and the need to return for febrile episodes is very challenging to achieve. It is not 
surprising that failure to complete treatment was 11%, given these difficulties. A large 
amount of effort and expense has been and continues to be made to establish the outcome 
of the children and ascertain whether they have had any untoward events; this is vital in 
assessing the effectiveness of the treatment schedule.     
 
The challenges in setting up an ALL treatment programme in LIC are many and vary according 
to specific local circumstances. The commitment at QECH to providing care for children with 
ALL despite limited resources demonstrates how much can be achieved.  It is hoped that the 
lessons learned from the Blantyre experience can be used in other similarly resourced units 
planning to start treatment for children with ALL. (Table 2)  
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Figure and table legends. 
Table 1.  Clinical characteristics of children treated on ALL protocol 3 (n=149).  
Table 2. Summary of essential factors in setting up a treatment protocol for ALL in a low- 
income setting. 
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Deaths by treatment stage by year (% of 
patients entering each stage) 
Malawi ALL Protocol 






Number of patients   145       
Median age (range)   8 (0.5-18)       
Sex (Male:Female)   85:60       
Year of diagnosis 2013 13 2 (15) 6 (55) 1 (20) 
  2014 24 1 (4) 7 (30) 2 (13) 
  2015 25 2 (8) 7 (30) 2 (13) 
  2016 38 1 (3) 9 (24) 1 (4) 
  2017 23 4 (17) 3 (16) 5 (31) 
  2018 20 1 (5) 5 (26) 2 (14) 
  2019 2       
Median follow up (years)   0.51       
            
HIV status Negative 131       
  Positive 1       
            
Nutrition Poor 45       
  Fair 63       
  Good 27       
            
Median White Blood Cell count (range)   35 (0-540)       
            
Median Haemoglobin (range)   
5.6 (1.8-
13.6)       
            
Median Platelets (range)   28 (0-595)       
            
Median Liver size (range)   0.5 (0-12)       
            
Median Spleen size (range)   3 (0-25)       
            
Lymphadenopathy  No 67       
  Yes 77       
            
Bone Pain No 101       
  Yes 43       
            
Pyrexia No 31       
  Yes 113       
            
Median length of history (range)   30 (2-360)       
            
Median number of blood transfusions (range)   1 (0-22)       
            
24 month event free survival percentage(95% CI)   27 (19-39)       
            
24 month overall survival percentage  (95% CI)   20 (14-29)       
            




CI p   
Sex (female vs male) 1.56 1.01 2.40 0.04   
No. of blood transfusion prior to admission 1.09 1.00 1.20 0.04   
            
Multivariable analysis           
Sex (female vs male) 1.65 1.07 2.54 0.02   
No. of blood transfusion prior to admission 1.11 1.02 1.2 0.02   
            
 
 
Table 3.  
 
 




• Treatment protocols should be simple and easy to follow 
• It is better to start with a less toxic protocol and gradually increase the 
intensity of treatment as staff become more confident in administering the 
protocol and are able to prevent or manage side effects 
• Timely diagnosis is critical to good outcome 
• The protocol can only be as intense as the supportive services of the hospital 
make possible. 
• The financial burdens of treatment and transport to hospital for families must 
be relieved to make completion of treatment feasible. 
 
Challenges of starting treatment protocols for acute lymphoblastic leukaemia in a low-
income setting – the Blantyre experience.  
 
Supplementary material.  
 
Methods.  
Initial examination and investigations of all children with a clinical diagnosis of ALL included 
weight, height and mid-arm circumference. Laboratory investigations included a full blood 
count, rapid HIV test, malaria test, stool and urine microscopy. Under ketamine sedation, a 
bone marrow aspirate (BMA) and cerebrospinal fluid (CSF) sample were taken. Slides of 
peripheral blood smears, BMA and CSF (cytospin was not available) were stained using 
Rapidiff stain kit (Clinical Service Laboratory, QECH, Cheshire, UK) and photographs of the 
slides, taken with  a Jenoptik camera (CT 13 with Prog Res Mac Capture Pro software) 
mounted on an Olympus microscope (CX31), were transmitted electronically for diagnostic 
confirmation in Newcastle, UK by an experienced haematologist (1). Initial intrathecal 
chemotherapy was given at the time of the diagnostic lumbar puncture. No 
immunocytochemistry or flow cytometry was performed on any of the specimens due to the 
lack of a flow cytometer or immunological stains.  Bone marrow samples were collected and 
shipped to the UK for retrospective genetic analysis, but the results were not available to 
influence treatment. Patient samples were screened by fluorescent in situ hybridisation (FISH) 
using commercially available probes for ETV6-RUNX1, BCR-ABL1 and KMT2A gene 
rearrangements as previously described (2). In addition, DNA was extracted and copy number 
alterations assessed for eight loci (IKZF1, CDKN2A/B, PAX5, BTG1, ETV6, EBF1, RB1 and the 
PAR1 region) using Multiplex Ligation-dependent Probe Amplification (MLPA), using the 
SALSA MLPA P335 kit (ALL-IKZF1, version C1) as previously described (3, 4). 
Treatment details.  
Children were treated from December 2009 until December 2012 on the Blantyre ALL 1 
protocol (42 children), from December 2012 until July 2013 on Blantyre ALL 2 (10 children) 
and from August 2013 until October 2019 on ALL 3 (145 children) (supplementary Figure 1). 
Children diagnosed from December 2009 until December 2018 were included in this report. 
The treatment protocols were developed in a risk adaptive manner after detailed 
consultations between the Blantyre and Newcastle teams, taking into account local 
conditions, supportive care and patient logistics. ALL 1 consisted of induction chemotherapy 
with prednisolone (40 mg/m2 per day in 2 divided doses) for 28 days with a week’s tapering 
from day 29-35, vincristine (1.5 mg/m2) weekly x 5, a single dose of cyclophosphamide at 300 
mg/m2 on day 1 and intrathecal methotrexate on day 1, 7 and 29. There were 20 weeks of 
maintenance with 5 days of prednisolone (40 mg/m2 per day in 2 divided doses), following 
the 4 weekly intravenous vincristine (1.5 mg/m2) and Intrathecal methotrexate. Daily oral 6 
mercaptopurine (60 mg/m2 /day) was continued throughout the maintenance period. In ALL 
2 the same protocol was used but a prednisolone pre phase of one week was added (40 
mg/m2 per day in 2 divided doses) - this was an interim protocol until ALL 3 was finalised. In 
ALL 3, cyclophosphamide was replaced by native asparaginase (various manufacturers, 
dependent on hospital supplies available) given at a dose of 6000 IU/m2 intramuscularly on 
alternate days, starting on day + 4, for 9 doses. In addition, after 8 weeks of interim 
maintenance  (as described above), an intensification block (week 14) consisting of 
doxorubicin 45 mg/m2) day 1 + 2, cytarabine 100 mg/m2 per dose bd x 10 doses, etoposide 
100 mg/m2  daily x 5 days, vincristine (1.5 mg/m2 day 1), prednisolone  40 mg/m2 per day in 
2 divided doses for 5 days and intrathecal methotrexate (day 1) was given. This was followed 
on count recovery by maintenance therapy as previously described (intrathecal methotrexate 
given every 12 weeks) up to a total of 104 weeks. Children were kept as inpatients for 
induction and intensification until their blood counts recovered. Monthly blood counts were 
performed although the results took a number of days and hence 6-mercaptopurine doses 
were adjusted a month in arrears. Cotrimoxazole prophylaxis, intermittent antimalarial 
prophylaxis and a bed net were given to all children. 
Statistical analysis. 
All statistical analyses were performed using R v3.6.2. Overall survival (OS) was defined as the 
time from date of diagnosis to death or date of last follow-up. Event-free survival (EFS) was 
defined as the time from diagnosis to first event (progression or relapse) or date of last follow-
up. Patients dying of other causes were censored at time of death. Using the survival package 
v3.1-8, Kaplan-Meier curves were constructed, and patient groups compared with log-rank 
tests. For univariable and multivariable Cox models, the proportionality assumption was 
tested using scaled Schoenfeld residuals. Missing data were assumed to be missing 
completely at random. For multivariable analysis, variables with greater than 10% missing 
values were removed from further consideration. Variables with fewer than 10% missing 
values were imputed 5 times using the aregImpute function from the rms package, v5.1-4. 
The modal value was selected for categorical variables and the mean value calculated for 
continuous data. Using forward likelihood ratio testing, multivariable models were 
constructed and limited to two variables because of cohort size. 
 
Description of Additional Clinical Characteristics. 
The median age at presentation was 8.0 years (6 months – 18 years), the median weight was 
19.9 kg (3.4-47 kg), 85 were male (58 %) and 60 were female (42 %).  Forty-five children (31%) 
had poor nutrition at diagnosis, 63 fair nutrition (43%), 27 (19%) good nutrition and 10 (7%) 
were unknown. This grading system is a subjective clinical judgement by the admitting doctor 
and is used for all children in the paediatric department. There was 1 child who was HIV 
positive, 13 whose HIV status was unknown and the remaining 131 children were HIV 
negative.  
The median presenting white blood cell count (WBC) was 35 x 109/L (0 to 540 x 109/L), 
median platelet count 28 x 109/L (0-595 x 109/L) and haemoglobin 5.6 g/dL (1.8 – 13.6 g/dL). 
 
The cause of death was thought to be disease in 84 children (79% of deaths), the majority of 
the remainder was unable to be determined, although sepsis was thought to be the major 
contributor. Seventy-eight (73%) patients died in hospital and 23 (21%) at home. The place 
of death was unknown in 6 patients (6%) (Figure 3). 
There was no significant difference in OS between cohorts (Protocol 1, OS 9%, 95% CI 3-25; 
Protocol 2, OS 10%,95% CI 2-66; Protocol 3 OS 20%, 95% CI 14-29, overall p=0.10). (Figure 4) 
Three of these children left the ward within the induction treatment period, 8 at last contact 
were alive and disease free (range of FU - 7 to 862 days, median 287 days), 2 alive with disease 
and 6 had died of their disease. Of these patients, 2 re-presented to the hospital with 
confirmed relapse. 
Univariable Cox proportional hazards models of EFS demonstrated that female sex was 
associated with a worse survival (HR=1.56, 95%CI 1.01-2.40, p=0.04). The number of blood 
transfusions received prior to admission was also associated with a worse survival (for each 
additional blood transfusion, HR=1.09, 95%CI 1.00-1.20, p=0.04). In multi-variable analysis, 
sex and number of blood transfusions prior to admission were independently prognostic 
(Supplementary table 1). 
Retrospective Genetic Analysis.  
Among the 145 patients treated on ALL-3, FISH and MLPA analyses were attempted on 37 
samples from 30 patients. Unfortunately, the failure rate for FISH was high (54/111, 48%) but 
much lower for MLPA (3/37, 8%). FISH for ETV6-RUNX1 was successful for 16 patients and 
two (13%) patients were positive (3 and 4 years old) with one additional case showing extra 
copies of RUNX1 indicative of tetrasomy 21. Further centromere FISH showed gains of 
chromosome X and 14 consistent with high hyperdiploidy. MLPA analysis was successful for 
27 patients and 13 (48%) patients harboured ≥1 CNA. The genes located on the short arm of 
chromosome 9 were deleted in 12/27 (44%) patients: CDKN2A/B deletion (n=5), PAX5 
deletion (n=5) and co-deleted (n=2).  Patients with CDKN2A/B/PAX5 had a female 
predominance among deletions (8 females; 4 males), high WCC (mean 71x109/L) and poor 
outcome (11/12 died).  Other deletions were rarer: ETV6 (n=2), EBF1 (n=1), RB1 (n=1). None 
of the patients had deletions affecting IKZF1, BTG1, or the PAR1 region. The frequency of 
ETV6-RUNX1 fusion in HIC is ~25% (2)) with the possible exception of a lower frequency 
(~12%) among Hispanics (5). The frequency of ETV6-RUNX1 fusion in our previous report (5) 
was 1/9 and in this study was 2/16 giving an overall estimated frequency of 12%. This is the 
first study to screen patients from Malawi for the common CNAs associated with ALL. Nearly 
half the tested patients harboured a deletion of CDKN2A/B and/or PAX5 which are both 
located on the short arm of chromosome 9. This frequency is marginally higher than the 30-
35% reported in UK cohorts(3). Nonetheless it is noteworthy that the 9p deletion patients in 
this cohort appear to be associated, like in the UK, with poor risk features – high WCC and 
poor outcome(6). Therefore, risk stratification of patients in Malawi, while challenging, 
should remain an achievable goal.  
 
Supplementary Figures. 
Supplementary Figure 1. Outline of treatment protocols for children with acute 
lymphoblastic leukaemia at the Queen Elizabeth Central Hospital in Blantyre. ALL 1 ran from 
December 2009 until December 2012, ALL 2 from December 2012 until July 2013 and ALL 3 
from August 2013. The weeks corresponding to the maintenance therapy are examples and 
continued for a total of 24 weeks for ALL1, 36 weeks for ALL 2 and 102 weeks for ALL3. 
Supplementary Figure 2. Bar plot showing the number of deaths at different stages per year 
diagnosed in the treatment protocol for children treated or intended to be treated on the 
ALL 3 protocol.  
Supplementary Figure 3. Flow chart showing clinical course of patients on the ALL3 
protocol.  
Supplementary Figure 4.  Event free (A) and overall survival (B) of Malawi ALL patients 
stratified by treatment protocol 1-3. P values from log-rank tests are shown.   
 
Supplementary tables.  
Supplementary Table 1. Identification of univariable and multivariable prognostic survival 
markers for children treated on the ALL 3 protocol. For each covariate, Cox models are 
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Supplementary Table 1. 
 
Univariable analysis         
          
Variable Hazard Ratio Lower 95%CI Upper 95%CI p value 
Sex (female vs male) 1.56 1.01 2.40 0.04 
No. of blood transfusion prior to admission 1.09 1.00 1.20 0.04 
HIV status 7.41 0.99 55.63 0.05 
Temperature 0.80 0.64 1.02 0.07 
Age (years) 1.05 0.99 1.11 0.09 
Place of death (hospital versus home) 0.66 0.40 1.09 0.10 
Pallor 1.60 0.83 3.10 0.16 
Weight (kg) 1.01 0.99 1.04 0.24 
Nutrition (versus malnourished) 0.78 0.48 1.26 0.31 
BonePain 0.80 0.50 1.27 0.34 
Length of history (days) 1.00 0.99 1.00 0.37 
History of bleeding 0.80 0.48 1.34 0.40 
Haemoglobin 0.96 0.87 1.06 0.42 
Lymphadenopathy 0.87 0.56 1.33 0.51 
History of Fever 0.86 0.53 1.38 0.52 
Failure to complete treatment 0.82 0.40 1.71 0.60 
Neutrophil count 1.00 0.97 1.03 0.78 
Platelet count 1.00 1.00 1.00 0.83 
Spleen size (cm) 1.00 0.96 1.05 0.85 
Liver size (cm) 0.99 0.91 1.09 0.88 
White blood cell count 1.00 1.00 1.00 0.95 
          
Multivariable analysis         
          
Variable         
Sex (female vs male) 1.65 1.07 2.54 0.02 
No. of blood transfusion prior to admission 1.11 1.02 1.20 0.02 
 
ALL 1 – 24 weeks total ALL 2 – 36 weeks total ALL 3 – 102 weeks total







1-2 years old - 8 mg
Intrathecal 2-3 years old - 10 mg 
methotrexate 3+ years old  - 12 mg
Cyclophosphamide 300mg/m2 - over 15 mins Dose
Vincristine 1.5 mg/m 2 per dose
Prednisolone 40 mg/m2/day  in 2 divided doses
then wean over 5 days
Day 1 8 15 22















1-2 years old - 8 mg
Intrathecal 2-3 years old - 10 mg 
methotrexate 3+ years old  - 12 mg
Doxorubicin 45 mg/m2 per dose
Etoposide 100 mg/m 2 per dose
cytarabine 100 mg/m 2 per dose
give hour after meal - not with milk 
6 mercaptopurine 60 mg/m2/day - in the evening 
Vincristine 1.5 mg/m 2 per dose
Prednisolone 40 mg/m2/day  in 2 divided doses
for 5 days
Cotrimoxazole Daily






















1-2 years old - 8 mg
Intrathecal 2-3 years old - 10 mg 
methotrexate 3+ years old  - 12 mg
Asparaginase 6000 IU/m 2 per dose (intramuscular) Dose
Day 4 - 1st dose
Vincristine 1.5 mg/m 2 per dose
Prednisolone 40 mg/m2/day  in 2 divided doses
then wean over 5 days
Day 1 8 15 22 Malawi ALL 3 














Prednisolone Dose given 
Bone marrow
1-2 years old - 8 mg
Intrathecal 2-3 years old - 10 mg 
methotrexate 3+ years old  - 12 mg
Prednisolone 40 mg/m2/day  in 2 divided doses
Prednisolone – 40 mg/m 2 /day x 7 days                                           
dosing may be started gradually for high 1 2 3 4 5 6 7
presenting WBC, mediastinal disease and if very unwell prednsiolone pre phase
Date 












1-2 years old - 8 mg
Intrathecal 2-3 years old - 10 mg 
methotrexate 3+ years old  - 12 mg
give hour after meal - not with milk 
6 mercaptopurine 60 mg/m2/day - in the evening 
may need to adjust dose after blood count
Vincristine 1.5 mg/m 2 per dose
Prednisolone 40 mg/m2/day  in 2 divided doses
for 5 days
Day 57 64 71 78 Malawi ALL 1 
















1-2 years old - 8 mg
Intrathecal 2-3 years old - 10 mg 
methotrexate 3+ years old  - 12 mg
give hour after meal - not with milk 
6 mercaptopurine 60 mg/m2/day - in the evening 
may need to adjust dose after blood count
Vincristine 1.5 mg/m 2 per dose
Prednisolone 40 mg/m2/day  in 2 divided doses
reduce over 5 days
Day 29 36 43 50 Malawi ALL 1 
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Intrathecal 2-3 years old - 10 mg 
methotrexate 3+ ye rs old  - 12 mg
Prednisolone 40 mg/m2/day  in 2 divided doses
Prednisolone – 40 mg/m 2 /day x 7 days                                           
dosing may be started gradually for high 1 2 3 4 5 6 7
presenting WBC, mediastinal disease and if very unwell prednsiolone pre phase
Date 
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for 5 days
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145 children  with ALL
Died prior to treatment
N = 11 (8%)
Children started treatment on ALL 3 
N = 134 (92 %)
Children on treatment 
n= 118  (81%)
Failure to complete treatment 
n = 16 (11 %)
Died in induction 
n =37 (26 %)
Died  at other time points *
n = 68 (47 %)
Children alive at time of follow up** 
n = 26 (18 %)
Died post intensification 
n=13 (9%)
Figure 3.
*   including 6 who failed to complete treatment
** including 10 who failed to complete treatment
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